Active, not recruitingPhase 2NCT04816604
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Principal Investigator
- Richard ArandaGossamer Bio Inc.
- Intervention
- GB002 (seralutinib)(drug)
- Enrollment
- 74 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2021 – 2027
Study locations (28)
- University of California, Davis Medical Center, Sacramento, California, United States
- Medical Corporation, Santa Barbara, California, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Norton Pulmonary Specialists, Louisville, Kentucky, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- NYU Langone Health, New York, New York, United States
- New York Presbyterian Hospital - Weill Cornell Medicine, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- INTEGRIS Baptist Medical Center, Inc., Oklahoma City, Oklahoma, United States
- Houston Methodist Hospital, Houston, Texas, United States
- University of Utah Health, Salt Lake City, Utah, United States
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04816604 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →